BioScrip Inc (BIOS) Receives a Buy from Barrington

Barrington analyst Michael Petusky maintained a Buy rating on BioScrip Inc (BIOSResearch Report) today and set a price target of $4. The company’s shares closed on Friday at $2.78.

Petusky observed:

“We suspect that additional cost synergies may be possible as well as longer-term revenue synergies.”

According to, Petusky is a 4-star analyst with an average return of 4.2% and a 51.2% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.

BioScrip Inc has an analyst consensus of Hold, with a price target consensus of $3.50.

See today’s analyst top recommended stocks >>

Based on BioScrip Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $15.36 million. In comparison, last year the company had a GAAP net loss of $1.46 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioScrip, Inc. engages in the provision of home infusion and home care management solutions. It partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. The company was founded in 1996 and is headquartered in Denver, CO.